Free Trial

BioCardia (BCDA) Competitors

$0.35
0.00 (0.00%)
(As of 05/28/2024 ET)

BCDA vs. CHRO, GENE, ONVO, IKT, COEP, TVGN, SRNE, SCNI, CELZ, and NSTGQ

Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), Organovo (ONVO), Inhibikase Therapeutics (IKT), Coeptis Therapeutics (COEP), Tevogen Bio (TVGN), Sorrento Therapeutics (SRNE), Scinai Immunotherapeutics (SCNI), Creative Medical Technology (CELZ), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.

BioCardia vs.

BioCardia (NASDAQ:BCDA) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, BioCardia had 6 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 0 mentions for Chromocell Therapeutics. BioCardia's average media sentiment score of 0.49 beat Chromocell Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company Overall Sentiment
BioCardia Neutral
Chromocell Therapeutics Neutral

Chromocell Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -2,208.76%. Chromocell Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
BioCardia-2,208.76% -3,638.68% -261.66%
Chromocell Therapeutics N/A N/A N/A

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioCardia received 10 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
BioCardiaOutperform Votes
10
47.62%
Underperform Votes
11
52.38%
Chromocell TherapeuticsN/AN/A

BioCardia currently has a consensus price target of $4.00, suggesting a potential upside of 1,042.86%. Given BioCardia's higher probable upside, equities analysts plainly believe BioCardia is more favorable than Chromocell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCardia
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Chromocell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Chromocell Therapeutics has lower revenue, but higher earnings than BioCardia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$480K19.91-$11.57M-$0.47-0.74
Chromocell TherapeuticsN/AN/AN/AN/AN/A

Summary

BioCardia beats Chromocell Therapeutics on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCDA vs. The Competition

MetricBioCardiaBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$9.56M$2.87B$5.00B$8.09B
Dividend YieldN/A2.24%2.74%3.96%
P/E Ratio-0.7428.61176.4818.43
Price / Sales19.91305.672,386.6172.31
Price / CashN/A162.8533.0728.77
Price / Book-5.004.124.944.39
Net Income-$11.57M-$45.89M$104.35M$213.55M
7 Day Performance-13.79%-3.27%-0.63%-0.80%
1 Month Performance-7.06%4.60%3.85%3.42%
1 Year Performance-81.18%2.83%5.47%7.53%

BioCardia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHRO
Chromocell Therapeutics
0 of 5 stars
$1.86
+2.2%
N/AN/A$10.50MN/A0.004Gap Down
GENE
Genetic Technologies
0 of 5 stars
$2.36
+3.5%
N/A-56.0%$10.41M$5.85M0.0060Short Interest ↓
News Coverage
ONVO
Organovo
0.8023 of 5 stars
$1.03
-4.6%
N/A-47.9%$10.34M$370,000.00-0.4718Analyst Forecast
Short Interest ↓
News Coverage
IKT
Inhibikase Therapeutics
1.5418 of 5 stars
$1.89
+1.6%
$23.00
+1,116.9%
-52.4%$12.25M$260,000.00-0.578Gap Up
COEP
Coeptis Therapeutics
2.3854 of 5 stars
$0.34
flat
$3.00
+790.2%
-86.5%$12.51M$80,000.00-0.645Short Interest ↓
Gap Up
TVGN
Tevogen Bio
0 of 5 stars
$0.86
+10.3%
N/AN/A$13.61MN/A0.0017Positive News
High Trading Volume
SRNE
Sorrento Therapeutics
0 of 5 stars
$0.01
flat
N/A-96.5%$7.17M$62.84M0.00949Gap Down
SCNI
Scinai Immunotherapeutics
0 of 5 stars
$3.79
-5.5%
N/AN/A$7.09MN/A-1.1633Stock Split
Short Interest ↓
Gap Up
CELZ
Creative Medical Technology
1.3576 of 5 stars
$4.40
+2.3%
N/A-21.5%$5.94M$10,000.00-1.184Short Interest ↓
Gap Up
NSTGQ
NanoString Technologies
0 of 5 stars
$0.12
-7.6%
N/AN/A$5.85M$127.26M-0.03550Gap Up

Related Companies and Tools

This page (NASDAQ:BCDA) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners